Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Subscribe To Our Newsletter & Stay Updated